1xbet.com

Tokyo, Japan -- Otsuka Pharmaceutical Co., Ltd. (Head 1xbet.comfice: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that the results 1xbet.com CSPS II^*, a large-scale clinical trial 1xbet.com cilostazol, were presented on February 26 in a late-breaking science session at the American Stroke Association's International Stroke Conference held in San Antonio, Texas. According to the report, patients taking cilostazol were less likely to suffer a stroke or develop bleeding requiring hospitalization compared to patients taking aspirin.

• *CSPS II: Cilostazol Stroke Prevention Study II

CSPS II was launched in December 2003 to investigate the efficacy 1xbet.com cilostazol in preventing recurrence 1xbet.com cerebral infarction and the safety 1xbet.com long-term administration 1xbet.com cilostazol (100mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral embolism) in a multi-center, double blind, parallel-group comparison with aspirin (81mg, once daily). The researchers analyzed results from 2,672 ischemic stroke patients treated in 278 institutions in Japan. Patients were followed through 2008. All patients had suffered non-cardioembolic ischemic stroke within 26 weeks 1xbet.com enrolment and their symptoms had remained stable.

In the randomized, double-blind study 1xbet.com nearly 2,700 patients with non-cardioembolic ischemic stroke, those treated with cilostazol were 25.7% less likely to suffer from a stroke than those who received aspirin, according to the presentation in the late-breaking science session at International Stroke Conference. Other findings shown below were also obtained in CSPS II.

• Strokes occurred in 82 1xbet.com 1,337 cilostazol-treated patients and in 119 1xbet.com 1,335 aspirin-treated patients.
• A hemorrhagic stroke or hemorrhage that required hospitalization occurred in 23 patients taking cilostazol and 57 1xbet.com those receiving aspirin - a significant difference.

"This study demonstrated for the first time that cilostazol significantly reduces the risk 1xbet.com recurrent ischemic stroke and the incidence 1xbet.com serious cerebral hemorrhage, compared to aspirin," said Yukio Shinohara, M.D., lead author 1xbet.com the study and hospital director at Federation 1xbet.com National Public Service Personnel Mutual Aid Associations Tachikawa Hospital in Tokyo, Japan."The primary implication 1xbet.com this trial is that the risk 1xbet.com re-attack 1xbet.com ischemic stroke in patients can be reduced without increasing the incidence 1xbet.com hemorrhage by oral administration 1xbet.com cilostazol. During the trial, we noted the incidence 1xbet.com recurrent stroke was very low, so we did not expect that there would be differences between the recurrence rate 1xbet.com stroke in the cilostazol and aspirin groups. However, the results showed a significant reduction in the recurrence rate, which surprised us. Although some 1xbet.com relatively minor complications other than bleedings were observed more in cilostazol-treated patients, while aspirin is used worldwide including Japan to prevent ischemic strokes, the findings in CSPS II provide us a significant impact on future clinical practice for the treatment 1xbet.com patients with ischemic stroke."

Otsuka Pharmaceutical Co., Ltd. strives to contribute to the health 1xbet.com people around the world based on its corporate philosophy 1xbet.com 'Otsuka-people creating new products for better health worldwide.'

Outline 1xbet.com CSPS II (Cilostazol Stroke Prevention Study II)

About Cilostazol

Cilostazol (Pletaal^®) was discovered and developed independently by Otsuka Pharmaceutical Co., Ltd. and launched in 1988 with improvement 1xbet.com ischemic symptoms including ulcers, pain and coldness associated with chronic arterial obstruction as the indication in Japan. In April 2003, secondary prevention 1xbet.com cerebral infarction (excluding cardiogenic cerebral embolism) was approved as the additional indication.